NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,316,400 | -7.4% | 109,000 | +9.0% | 0.91% | +0.1% |
| Q3 2022 | $4,660,000 | +35.8% | 100,000 | +27.8% | 0.90% | +28.2% |
| Q2 2022 | $3,431,000 | -5.1% | 78,277 | +56.6% | 0.71% | -25.0% |
| Q1 2022 | $3,617,000 | +27.5% | 50,000 | +42.9% | 0.94% | +19.9% |
| Q4 2021 | $2,837,000 | -18.7% | 35,000 | +16.7% | 0.78% | -21.8% |
| Q3 2021 | $3,491,000 | -44.6% | 30,000 | -21.1% | 1.00% | -42.1% |
| Q2 2021 | $6,300,000 | +12.9% | 38,000 | -5.0% | 1.73% | +8.8% |
| Q1 2021 | $5,580,000 | -63.4% | 40,000 | -54.5% | 1.59% | -64.8% |
| Q4 2020 | $15,233,000 | +60.8% | 88,000 | +29.4% | 4.53% | +56.4% |
| Q3 2020 | $9,472,000 | +5.7% | 68,000 | -9.3% | 2.90% | +8.0% |
| Q2 2020 | $8,960,000 | +124.1% | 75,000 | +87.5% | 2.68% | +52.4% |
| Q1 2020 | $3,999,000 | – | 40,000 | – | 1.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |